AlphaDetect, the nonprofit organization powered and funded by the Alpha-1 Foundation (A1F), today announced Beam Therapeutics ...

Researchers at Washington University School of Medicine in St. Louis have identified a previously unknown biological process ...

AIRNA, a biotech company pioneering RNA-editing therapeutics to transform the lives of patients with rare and common conditions, is presenting new preclinical data on its therapeutic candidate AIR-001 ...

B cash runway to mid-2029, pivotal SCD & AATD programs, and attractive valuation—review risks and opportunities now.

Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg ...

A live webcast of the presentation can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events.

A Uk-based doctor has highlighted six causes of liver cancer after the death of Nollywood actor Alexx Ekubo. He revealed his ...

Hosted virtual Analyst Day showcasing lead program KRRO-121’s potential to be a first-in-class transformational treatment for hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic ...

Researchers at WashU Medicine have identified a previously unknown biological process that may help explain why only a subset of patients with alpha1-antitrypsin deficiency develop liver disease. In ...

On track to file IND and/or CTA for PM577 in Wilson Disease in H1 2026 and for PM647 in AATD mid-2026; initial clinical data from both programs expected in 2027 -- -- Continued regulatory dialogue ...

Beam Therapeutics BEAM incurred a loss of 91 cents per share in the first quarter of 2026, wider than the Zacks Consensus ...

RALEIGH, NC (WWAY)– Mother’s Day is special for most people, but for one mom, every moment is a gift with her youngest son. Four-year-old Corbin now spends his days running, laughing, going to daycare ...